Cargando…
Targeted Therapy for Medullary Thyroid Cancer: A Review
Medullary thyroid cancers (MTCs) constitute between 2 and 5% of all thyroid cancers. The 10-year overall survival (OS) rate of patients with localized disease is around 95% while that of patients with regional stage disease is about 75%. Only 20% of patients with distant metastases at diagnosis surv...
Autores principales: | Priya, S. R., Dravid, Chandra Shekhar, Digumarti, Raghunadharao, Dandekar, Mitali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635342/ https://www.ncbi.nlm.nih.gov/pubmed/29057215 http://dx.doi.org/10.3389/fonc.2017.00238 |
Ejemplares similares
-
The Science and Art of Reviewing
por: Digumarti, Raghunadharao
Publicado: (2017) -
From the editor's desk
por: Digumarti, Raghunadharao
Publicado: (2016) -
Chronic myeloid leukemia: An Indian scenario
por: Digumarti, Raghunadharao
Publicado: (2016) -
Design of new drugs for medullary thyroid carcinoma
por: Li, Yanqing, et al.
Publicado: (2022) -
Update on Targeted Therapy in Medullary Thyroid Cancer
por: Okafor, Christian, et al.
Publicado: (2021)